Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: An asthma sufferer wears a paper face mask as she is attended by nurses in this undated file image. REUTERS/Jason Reed The findings were published in the journal Lancet together with two other studies, which found that runny noses and wheezing early on in life may be strong predictors of asthma. In the first study, researchers pored through data provided by parents of more than 205,000 children and found paracetamol use in the first year of life was associated with a 46 percent higher risk of asthma by the time the children were 6 or 7 compared to those never exposed to the drug. Known as acetaminophen in the United States, where it is widely sold under the brand Tylenol, it is used to relieve fever, minor aches and pain, and is used in a liquid suspension for children. Medium use of paracetamol in the past 12 months increased asthma risk by 61 percent, while high dosages of once a month or more in the past year raised the risk by over three times. Medium use was defined as once per year or more, but less than once a month. Suspicions of a possible link between paracetamol and asthma emerged in recent years when experts observed an increased use of the drug to a simultaneous rise in asthma prevalence worldwide. One theory is that paracetamol reduces antioxidants in the body. Some experts think antioxidants, which stop unstable molecules known as free radicals from doing too much damage, can lower the risk of cancer, heart disease and other ailments. "Paracetamol can reduce antioxidant levels and ... that can give oxidative stress in the lungs and cause asthma," one of the researchers, Richard Beasley at the Medical Research Institute of New Zealand, told Reuters in a telephone interview. As with asthma, monthly use of paracetamol doubled the risk of eczema and trebled that of rhinoconjunctivitis repetitive sneezing, rhinorrhea, nasal congestion and hay fever by the time children were 6 or 7, the study found. However, the researchers stressed paracetamol should remain the preferred drug to relieve pain and fever in children because its alternative, aspirin, was linked to the risk of Reye's syndrome, a rare but serious complication in children. "The findings do lend support to the current guidelines of the World Health Organization, which recommend that paracetamol should not be used routinely, but should be reserved for children with a high fever (38.5 Celsius or above)," they wrote. Another study in The Lancet found that rhinitis, or hay fever and other allergic reactions causing a runny nose, was a strong predictor of asthma that develops in adulthood. Researchers monitored 6,461 people in 14 countries who were free of asthma at the start of study for more than 8 years. Those who suffered rhinitis and were allergic to an assortment of agents like house dust mites, cat, grass and birch were 3.5 times more likely to develop asthma later on compared to those who suffered no allergies nor rhinitis. The third study in Arizona in the United States found wheezing early in life may be an ominous sign of asthma developing in adulthood. Researchers pored through data on 849 people going back 22 years to the time they were babies. Of 181 cases of active asthma, 49 were newly diagnosed, of which 35 were women. "In over 70 percent of people with current asthma and 63 percent of those with newly diagnosed asthma at age 22 years, episodes of wheezing had happened in the first three years of life or were reported by parents at age six years," wrote the researchers at the Arizona Respiratory Center. In an accompanying comment, Suzanne Lau of Charite University Medicine in Germany, wrote: "These findings identify a population at risk of chronic obstructive airway disease in early adulthood, and they already showed a predisposition during preschool years." Lau was not involved in the study. Claim: Paracetamol use may raise asthma risk in children.

Output: Infants who have been given the common pain reliever paracetamol may have a higher risk of developing asthma and eczema by the time they are 6 or 7, a large study covering children in 31 countries has found.

Input: Consider Input: Paragraph: Although the release doesn't give actual costs of warfarin versus some of the newer drugs, or factor in the cost of the usual monthly blood testing required of those taking the drug, it does note the cost of the gene testing used for the study, and that the $200 price tag is now less than a month's prescription of one of the newer anti-coagulants on the market. The release gives results in both actual numbers of patients and the percentage of reduction of adverse events in those given the genetic test and a comparison group. Although it does so in general terms, the release covers the essentials: the risk of using blood thinners like warfarin and the risks of not using them. The release offers a good description of the design of the study. It was randomized and enrolled more than 1,600 older patients at high risk of blood clots following surgeries. The release explains that one group received warfarin dosing based on standard factors (age, height and weight) and the second group was dosed using these clinical factors plus their genetic variants. The release also offers a detailed breakdown on how many fewer side effects occurred among patients had genetic testing completed compared to those who didn't. No mongering here. Nicely done and quite complete. Although the release briefly mentions the availability of a "newer anticoagulant," it should have included a sentence or two about these newer injectable drugs and their overall risks and benefits in comparison to warfarin. It would also have been helpful to tell readers whether the genetic testing that appears to play a role in safer warfarin dosing would have clinical relevance for informing the use of the new blood thinners as well. The fact is that genetic testing is irrelevant for the newer anti-coagulants because they operate in a completely different manner. But all the blood thinners old and new carry the same risk of bleeding. The problem with warfarin is the variability in blood levels which requires frequent monitoring, hence the genetic tests to guide dosing. The careful reader will get it: testing for these genetic variants is still an experimental practice for the most part, and further testing of how the mutations affect warfarin is needed. But the release could have been more explicit in saying that no one is yet recommending genetic testing for millions of warfarin users. While the genetic tests are "available" in the sense that anyone can order them for the most part, they are not routinely used clinically and probably wouldn't be covered by insurance so in that sense they are not widely available to most people. The release describes how the genetic test used in the new study differs from previous similar studies. Overall the language is careful and contextual. The headline should have been toned back a bit to note that this is early research and more study is needed before concluding that "Genetic testing helps set safe dose of common blood thinner," as the headline now states. Claim: Genetic testing helps set safe dose of common blood thinner

Output: This news release describes results of a study designed to learn whether testing for the presence of three gene variants could make dosing with the blood thinner warfarin safer for patients given the drug to prevent blood clots after joint replacement surgery. The study found a modest reduction in the risk of bleeding or clots (from over- or under-dosing) in those whose regimens were developed in part by genetic testing for the variants, compared to those whose doses were calculated without the genetic testing. The release does an overall good job in describing the study, its purpose and design; and in quantifying the results. It could have been even stronger if it had included more information about newer alternatives to warfarin that are growing in use and an explicit statement that no one is yet recommending routine genetic testing for the variants based on this study. And although the headline somewhat over promises clinical benefit at this point in time, thoughtful readers will come away with a decent understanding of the context of the research and its potential impact. Some estimates put the number of Americans regularly taking the clot-preventing blood thinner warfarin and several newer anticoagulants at more than six million. Warfarin (sold under the brand name Coumadin) requires frequent blood testing to address risks of overdoses (and potentially lethal bleeding) and under-dosing (ineffective prevention of strokes and other blood clots). Because warfarin is cheap, and its effects are reversible with vitamin K, research designed to make it easier and safer for patients to take is likely to be highly newsworthy for them and their caregivers.

Input: Consider Input: Paragraph: A right lateral view chest x-ray of a healthy lung is seen in an undated handout photo. REUTERS/DCD/Dr. Thomas Hooten/Handout Chronic obstructive pulmonary disease, or COPD, is the fourth-leading cause of death in the United States and the world and is on the rise. There is no cure. The researchers found that a master gene called NRF2, which turns on other genes involved in protecting the lungs from pollution and cigarette smoke, was not working properly in smokers with advanced COPD, which affects 210 million people worldwide. And they said a compound found in broccoli might help correct this problem. "This work clearly demonstrates that a decline in our antioxidant system is involved in progression of COPD, which could also be the cause for other environmental disease," Shyam Biswal of Johns Hopkins School of Medicine said in a statement. There are no treatments for COPD, a condition that includes emphysema, chronic bronchitis and some types of serious chronic asthma. Smoking is by far the leading cause of COPD, but environmental factors such as pollution play a role. In earlier studies, Biswal found that mice with poorly working NRF2 genes developed severe emphysema. His current study in the American Journal of Respiratory and Critical Care Medicine looked at tissue samples of smokers with COPD and those without it. They found that the lungs of people with COPD had decreased levels of antioxidants that were regulated by the NRF2 gene. The sicker the patients, the lower the levels they found. But they also found that sulforaphane, a compound that occurs naturally in broccoli and wasabi, was able to restore the function of the NRF2 gene in human tissue. "These are the keys we are looking for in terms of having a more specific intervention," Dr. John Heffner, past president of the American Thoracic Society, said in a telephone interview. "If we can discover the primary triggers that induce lung damage in smokers we will be able to slow the progression of this highly lethal condition," Heffner said. He said the study, which he was not involved in, pointed to a genetic switch that turns off the body's defenses against cigarette smoke and leads to lung damage. "Compounds that target that switch may be able to turn it back on to prevent the progression of COPD." He said it was too early to suggest eating broccoli would cure COPD. Other clinical trials of antioxidants have failed to show a benefit. "We are hoping to initiate human trials with these more specific compounds that target what has been shown to be the most important antioxidant system," he said. Claim: Gene switch malfunctioning in chronic lung disease.
Output: Smokers who have chronic lung disease are much more likely to have a poorly working antioxidant defense system than other smokers, a finding that may lead to new treatments, U.S. researchers said on Friday.